EP2496589B1 - Neue chirale phosphorliganden - Google Patents

Neue chirale phosphorliganden Download PDF

Info

Publication number
EP2496589B1
EP2496589B1 EP10774398.1A EP10774398A EP2496589B1 EP 2496589 B1 EP2496589 B1 EP 2496589B1 EP 10774398 A EP10774398 A EP 10774398A EP 2496589 B1 EP2496589 B1 EP 2496589B1
Authority
EP
European Patent Office
Prior art keywords
membered
formula
alkyl
tert
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP10774398.1A
Other languages
English (en)
French (fr)
Other versions
EP2496589A1 (de
Inventor
Bo QU
Chris Hugh Senanayake
Wenjun Tang
Xudong Wei
Nathan K. Yee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of EP2496589A1 publication Critical patent/EP2496589A1/de
Application granted granted Critical
Publication of EP2496589B1 publication Critical patent/EP2496589B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0073—Rhodium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Definitions

  • the present invention relates to a series of novel chiral phosphorus ligands and their metal complexes as catalysts for applications in asymmetric hydrogenation. More particularly, the present invention relates to the transition metal complexes of these novel phosphine ligands and their use as catalysts in asymmetric hydrogenation.
  • Asymmetric hydrogenation utilizing molecular hydrogen to reduce prochiral olefins, ketones, and imines has become one of most efficient methods for constructing chiral compounds. It also accounts for the major asymmetric catalytic transformation at commercial scales. Development of efficient chiral phosphorus ligands is essential for the success of asymmetric hydrogenation.
  • Known chiral phosphorus ligands in this field include Knowles' DIPAMP [ Knowles, W. S. Acc. Chem. Res. 1983, 16, 106 ], Kagan's DIOP [ Kagan et al, J. Am. Chem. Soc. 1972, 94, 6429 ], Noyori's BINAP [ Noyori, R. Chem. Soc. Rev.
  • FIG. 1 shows an x-ray crystal structure of Rh[(nbd)((2 R ,2' R ,3 R ,3' R )-BIBOP)]BF 4 (the H atoms are omitted), where each of the letters on the atoms (C, O, P, Rh, B, and F) refer to carbon, oxygen, phosphorus, rhodium, boron and fluorine, respectively.
  • the present invention relates to novel phosphine ligands, novel metal complexes containing the novel phosphine ligands of the invention, and methods of using the novel metal complexes to carry out asymmetric hydrogenations as described below.
  • the present invention relates to a compound of formula ( Ia ), ( Ib ), or a mixture thereof ("the phosphine ligand of the invention”): wherein :
  • the invention relates to a compound of formula ( Ia ), ( Ib ), or a mixture thereof, according to any of the preceding embodiments, wherein R 1 is -(C 1 -C 6 )alkyl selected from -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -C(CH 2 CH 3 ) 3 , or -C(CH 2 CH 3 )(CH 3 ) 2 .
  • the invention relates to a compound of formula ( Ia ), ( Ib ), or a mixture thereof, according to the broadest embodiment described above, wherein R 1 is -(C 3 -C 10 )carbocyclyl selected from cyclopentyl, cyclohexyl, and 1-adamantyl.
  • the invention relates to a compound of formula ( Ia ), ( Ib ), or a mixture thereof, according to the broadest embodiment described above, wherein R 1 is -(C 6 -C 10 )aryl selected from phenyl, ortho-tolyl, para-tolyl, 3,5-dimethylphenyl, 3,5-di-t-butylphenyl, 3,5-di-CF 3 -phenyl, ortho-CF 3 -phenyl, ortho-anisyl, and naphthyl.
  • the invention relates to a compound of formula ( Ia ), ( Ib ), or a mixture thereof, according any of the preceding embodiments, wherein R 2 is H, -CH 3 or -OCH 3 .
  • the invention relates to a compound of formula ( Ia ), ( Ib) , or a mixture thereof, according to the broadest embodiment described above wherein R 2 is phenyl.
  • the invention relates to a compound of formula ( Ia ), ( Ib ), or a mixture thereof, according any of the preceding embodiments, wherein R 4 is -H.
  • the invention relates to a compound of formula ( Ia ), ( Ib ), or a mixture thereof, according to the broadest embodiment described above, wherein R 4 is -(C 1 -C 6 )alkyl optionally substituted with 1 to 3 substituents independently selected from -OCH 3 , -(C 3 -C 6 )cycloalkyl, phenyl, and -(5- to 6-membered)heteroaryl.
  • the invention relates to a compound of formula ( Ia ), ( Ib ), or a mixture thereof, according to the embodiment described immediately above, wherein R 4 is -CH 2 (chiral oxazoline) or -CH 2 ( ortho -substituted pyridine).
  • the invention relates to a compound of formula ( Ia ), ( Ib ), or a mixture thereof, according to the broadest embodiment described above, wherein R 4 is a -(5- to 6-membered)heteroaryl selected from ortho -substituted pyridine, oxazoline, and chiral oxazoline.
  • the invention relates to a compound of formula ( Ia ), ( Ib ), or a mixture thereof, according to any of the preceding embodiments, wherein R 3 is -PR 7 R 8 or a group of formula (A) ("the bis-phosphine ligand of the invention")
  • the invention relates to a bis-phosphine ligand of the invention, wherein R 1 is -C(CH 3 ) 3 ; R 2 is -H, -CH 3 , -OCH 3 , or phenyl; and R 3 is -PR 7 R 8 .
  • the invention relates to a bis-phosphine ligand of the invention, wherein R 7 and R 8 are each independently H, -(C 1 -C 6 )alkyl, or -(C 3 -C 6 )cycloalkyl.
  • the invention relates to a bis-phosphine ligand of the invention, wherein R 7 and R 8 are each -C(CH 3 ) 3 .
  • the invention relates to a bis-phosphine ligand of the invention, wherein X is O, R 1 is -C(CH 3 ) 3 ; R 2 is -H, -CH 3 , -OCH 3 , or phenyl; and R 3 is -PR 7 R 8 .
  • the invention relates to a bis-phosphine ligand of the invention, wherein R 3 is a group of formula (A) or (B).
  • the invention relates to a bis-phosphine ligand of the invention, according to the embodiment described immediately above, wherein R 1 is -C(CH 3 ) 3 ; and R 2 is -H, -CH 3 , -OCH 3 , or phenyl.
  • the invention relates to a bis-phosphine ligand of the invention, wherein X is O; R 1 is -C(CH 3 ) 3 ; and R 2 is -H, -CH 3 , -OCH 3 , or phenyl; and R 3 is a group of formula of formula (A) or (B)..
  • the invention relates to a bis-phosphine ligand of the invention having the formula ( IIa ) or ( IIb ) wherein:
  • the invention relates to a bis-phosphine ligand of the invention having the formula ( IIIa ) or (IIIb): wherein
  • the invention relates to a phosphine ligand of the invention selected from:
  • the invention relates to complexes formed between a transition metal and the phosphine ligands of the invention. Accordingly, in one embodiment, the invention relates to a metal complex of formula ( IVa ), (IVb), (Va) or (Vb) ("the metal complexes of the invention"): wherein
  • the invention relates to a metal complex of the invention wherein M is Rh and n is 1.
  • the invention relates to a metal complex of the invention according to any of the two embodiments described immediately above, wherein A - is BF 4 - , SbF 6 - , TfO - ,B(C 6 H 5 ) 4 - , B[3,5-(CF 3 ) 2 C 6 H 3 ] 4 - , or PF 6 - .
  • the invention relates to a metal complex of the invention according to any of the three embodiments described immediately above, wherein M is Rh, A - is BF 4 - , and n is 1.
  • the invention relates to a metal complex of the invention according to any of the four embodiments described immediately above, wherein R 1 is -C(CH 3 ) 3 , and R 2 is -H, -CH 3 , -OCH 3 , or phenyl.
  • the invention in another embodiment, relates to a metal complex of the invention wherein L 1 and L 2 together represent a diolefin selected from norbornadiene and cyclooctadiene.
  • the invention relates to a metal complex of the invention, wherein the metal complex is of formula ( IVa ).
  • the invention relates to a metal complex of the invention according to the embodiment immediately above, wherein M is Rh, A - is BF 4 - ; and n is 1.
  • the invention relates to a metal complex of the invention according to the embodiment immediately above, wherein L 1 and L 2 together represent a diolefin selected from norbomadiene and cyclooctadiene.
  • the invention relates to a metal complex of the invention, wherein the metal complex is of formula (Va).
  • the invention relates to a metal complex of the invention according to the embodiment immediately above, wherein M is Rh, A - is BF 4 - ; and n is 1.
  • the invention relates to a metal complex of the invention according to the embodiment immediately above, wherein L 1 and L 2 together represent a diolefin selected from norbomadiene and cyclooctadiene.
  • the invention relates to a metal complex of the invention, wherein the metal complex is of formula ( IVb ).
  • the invention relates to a metal complex of the invention according to the embodiment immediately above, wherein M is Rh, A - is BF 4 - ; and n is 1.
  • the invention relates to a metal complex of the invention according to the embodiment immediately above, wherein L 1 and L 2 together represent a diolefin selected from norbomadiene and cyclooctadiene.
  • the invention relates to a metal of the invention, wherein the metal complex is of formula (Vb).
  • the invention relates to a metal complex of the invention according to the embodiment immediately above, wherein M is Rh, A - is BF4 - ; and n is 1.
  • the invention relates to a metal complex of the invention according to the embodiment immediately above, wherein L 1 and L 2 together represent a diolefin selected from norbornadiene and cyclooctadiene.
  • the invention relates to a metal complex of the invention selected from:
  • the invention relates to a process for the asymmetric hydrogenation of a compound having a carbon-carbon or carbon-heteroatom double bond ("the asymmetric hydrogenation process of the invention"), the process comprising allowing said compound having a carbon-carbon or carbon-heteroatom double bond to react with hydrogen in the presence of a catalytic amount of the metal complex of the invention described in any of the embodiments above.
  • the asymmetric hydrogenation process of the invention a process for the asymmetric hydrogenation of a compound having a carbon-carbon or carbon-heteroatom double bond
  • the process comprising allowing said compound having a carbon-carbon or carbon-heteroatom double bond to react with hydrogen in the presence of a catalytic amount of the metal complex of the invention described in any of the embodiments above.
  • Non-limiting examples of carbon-heteroatom double bonds include those formed between carbon and nitrogen, oxygen, or sulfur.
  • carbon-heteroatom double bond is formed between carbon and nitrogen or carbon and oxygen.
  • the invention relates to the asymmetric hydrogenation process of the invention in the embodiment described immediately above, wherein L 1 and L 2 together represent norbornadiene.
  • the invention relates to the asymmetric hydrogenation process of the invention in the broadest embodiment described above, wherein L 1 and L 2 together represent octadiene.
  • the invention relates to the asymmetric hydrogenation process of the invention in any of the embodiments described above, wherein M is Rh, A - is BF 4 - , and n is 1.
  • the invention relates to the asymmetric hydrogenation process of the invention in any of the embodiments described above, wherein R 1 is -C(CH 3 ) 3 ; R 2 is - H, -CH 3 , -OCH 3 , or phenyl; and R 7 and R 8 are each -C(CH 3 ) 3 .
  • compounds of the invention refers to the phosphine ligands of the invention (including bis-phosphine ligands of the invention) and the metal complexes of the invention.
  • Compounds of the invention also include their isotopically-labelled forms.
  • An isotopically-labelled form of a compound of the present invention is identical to said compound of the invention but for the fact that one or more atoms of said compound of the invention have been replaced by an atom or atoms having an atomic mass or mass number different from the atomic mass or mass number of said atom which is usually found in nature.
  • isotopes which are readily available commercially and which can be incorporated into an active agent of a combination of the present invention in accordance with well established procedures, include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, e.g ., 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, and 36 Cl, respectively.
  • a compound of the present invention which contains one or more of the above-mentioned isotopes and/or other isotopes of other atoms is contemplated to be within the scope of the present invention.
  • the invention includes the use of any compounds of described above containing one or more asymmetric carbon atoms may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Isomers shall be defined as being enantiomers and diastereomers. All such isomeric forms of these compounds are expressly included in the present invention.
  • Each stereogenic carbon may be in the R or S configuration, or a combination of configurations.
  • Some of the compounds of the invention can exist in more than one tautomeric form.
  • the invention includes methods using all such tautomers.
  • C 1-6 alkoxy or "O(C 1 - 6 )alkyl” is a (C 1-6 )alkyl with a terminal oxygen, such as methoxy, ethoxy, propoxy, butoxy.
  • All alkyl, alkenyl, and alkynyl groups shall be understood as being branched or unbranched where structurally possible and unless otherwise specified. Other more specific definitions are as follows:
  • N is not substituted then it is NH.
  • heteroatoms may replace either terminal carbon atoms or internal carbon atoms within a branched or unbranched carbon chain.
  • groups can be substituted as herein above described by groups such as oxo to result in definitions such as but not limited to: alkoxycarbonyl, acyl, amido and thioxo.
  • nitrogen and sulfur include any oxidized form of nitrogen and sulfur and the quaternized form of any basic nitrogen.
  • a -S-C 1-6 alkyl radical unless otherwise specified, shall be understood to include -S(O)-C 1-6 alkyl and -S(O) 2 -C 1-6 alkyl.
  • (C 3-10 )carbocycle refers to a nonaromatic 3 to 10-membered (but preferably, 3 to 6-membered) monocyclic carbocyclic radical or a nonaromatic 6 to 10-membered fused bicyclic, bridged bicyclic, or spirocyclic carbocyclic radical.
  • the C 3-10 carbocycle may be either saturated or partially unsaturated, and the carbocycle may be attached by any atom of the cycle which results in the creation of a stable structure.
  • Non-limiting examples of 3 to 10-membered monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptanyl, cycloheptenyl, and cyclohexanone.
  • Non-limiting examples of 6 to 10-membered fused bicyclic carbocyclic radicals include bicyclo[3:3.0]octane, bicyclo[4.3.0]nonane, and bicyclo[4.4.0]decanyl (decahydronaphthalenyl).
  • Non-limiting examples of 6 to 10-membered bridged bicyclic carbocyclic radicals include bicyclo [2.2.2]heptanyl, bicyclo[2.2.2]octanyl, and bicyclo[3.2.1]octanyl.
  • Non-limiting examples of 6 to 10-membered spirocyclic carbocyclic radicals include but are not limited to spiro[3,3]heptanyl, spiro[3,4]octanyl and spiro[4,4]heptanyl.
  • (C 6-10 )aryl refers to aromatic hydrocarbon rings containing from six to ten carbon ring atoms.
  • C 6-10 aryl includes monocyclic rings and bicyclic rings where at least one of the rings is aromatic.
  • Non-limiting examples of C 6-10 aryls include phenyl, indanyl, indenyl, benzocyclobutanyl, dihydronaphthyl, tetrahydronaphthyl, naphthyl, benzocycloheptanyl and benzocycloheptenyl.
  • (5 to 11-membered)heterocycle refers to a stable nonaromatic 4-8 membered monocyclic heterocyclic radical or a stable nonaromatic 6 to 11-membered fused bicyclic, bridged bicyclic or spirocyclic heterocyclic radical.
  • the 5 to 11-membered heterocycle consists of carbon atoms and one or more, preferably from one to four heteroatoms chosen from nitrogen, oxygen and sulfur.
  • the heterocycle may be either saturated or partially unsaturated.
  • Non-limiting examples of nonaromatic 4-8 membered monocyclic heterocyclic radicals include tetrahydrofuranyl, azetidinyl, pyrrolidinyl, pyranyl, tetrahydropyranyl, dioxanyl, thiomorpholinyl, 1,1-dioxo-1 ⁇ 6 -thiomorpholinyl, morpholinyl, piperidinyl, piperazinyl, and azepinyl.
  • Non-limiting examples of nonaromatic 6 to 11-membered fused bicyclic radicals include octahydroindolyl, octahydrobenzofuranyl, and octahydrobenzothiophenyl.
  • Non-limiting examples of nonaromatic 6 to 11-membered bridged bicyclic radicals include 2-azabicyclo[2.2.1]heptanyl, 3-azabicyclo[3.1.0]hexanyl, and 3-azabicyclo[3.2.1]octanyl.
  • Non-limiting examples of nonaromatic 6 to 11-membered spirocyclic heterocyclic radicals include 7-aza-spiro[3,3]heptanyl, 7-spiro[3,4]octanyl, and 7-aza-spiro[3,4]octanyl.
  • (5 to 11-membered)heteroaryl refers to an aromatic 5 to 6-membered monocyclic heteroaryl or an aromatic 7 to 11-membered heteroaryl bicyclic ring where at least one of the rings is aromatic, wherein the heteroaryl ring contains 1-4 heteroatoms such as N, O and S.
  • Non-limiting examples of 5 to 6-membered monocyclic heteroaryl rings include furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, pyrazolyl, pyrrolyl, imidazolyl, tetrazolyl, triazolyl, thienyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, and purinyl.
  • Non-limiting examples of 7 to 11-membered heteroaryl bicyclic heteroaryl rings include benzimidazolyl, quinolinyl, dihydro-2 H -quinolinyl, isoquinolinyl, quinazolinyl, indazolyl, thieno[2,3-d]pyrimidinyl, indolyl, isoindolyl, benzofuranyl, benzopyranyl, benzodioxolyl, benzoxazolyl and benzothiazolyl.
  • heteroatom as used herein shall be understood to mean atoms other than carbon such as O, N, and S.
  • halogen as used in the present specification shall be understood to mean bromine, chlorine, fluorine or iodine.
  • alkyl a non-limiting example would be -CH 2 CHF 2 , -CF 3 etc.
  • olefin refers to an unsaturated hydrocarbon containing carbon atoms linked by a double bond (i.e., an alkene) such as, for example, ethylene, propene, 1-butene, 2-butene, styrene, norbornadiene, or cyclooctadiene.
  • alkene such as, for example, ethylene, propene, 1-butene, 2-butene, styrene, norbornadiene, or cyclooctadiene.
  • diolefin refers an unsaturated hydrocarbon containing two pairs of carbon atoms linked by double bonds, e.g., norbornadiene, or cyclooctadiene.
  • the compounds of the invention may be made using the general synthetic methods described below.
  • the invention also provides processes for making compounds of formula Ia, Ib, IIa, IIb, IIIa, IIIb, IVa, IVb, Va and Vb.
  • R 1 , R 2 , R 3 R 4 , R 7 , R 8 , L 1 , L 2 , A, M and n in the formulas below shall have the meaning of R 1 , R 2 , R 3 R 4 , R 7 , R 8 , L 1 , L 2 , A, M and n in formula Ia, Ib, IIa, IIb, IIIa, IIIb, IVa, IVb, Va and Vb of the invention described herein above.
  • reaction conditions and reaction times may vary depending on the particular reactants used. Unless otherwise specified, solvents, temperatures, pressures, and other reaction conditions may be readily selected by one of ordinary skill in the art. Specific procedures are provided in the Examples section. Typically, reaction progress may be monitored by thin layer chromatography (TLC), if desired, and intermediates and products may be purified by chromatography on silica gel and/or by recrystallization.
  • TLC thin layer chromatography
  • intermediates and products may be purified by chromatography on silica gel and/or by recrystallization.
  • reaction of dimethoxy phenyllithium VI with a dichlorophosphine of formula VII, in a suitable solvent, in the presence of an alkyl magnesium chloride and hydrogen peroxide provides a phosphine oxide of formula VIII.
  • Iodination of the phosphine oxide VIII, in a suitable solvent, in the presence of a suitable base provides the iodinated intermediate of formula IX.
  • Demethylation of the methoxy groups of compound IX by a reagent such as boron tribromide (BBr 3 ) followed by cyclization provides the corresponding cyclized intermediate of formula X.
  • reaction of a compound of formula XIIb, obtained via Scheme 1, with a phosphorus chloride of formula XIV, in the presence of a suitable base and hydrogen peroxide provides a bisphosphine oxide of formula XVb.
  • Reduction of the bisphosphine oxide XVb as in Scheme 1 provides a compound of formula IIIb.
  • a compound of formula XIIa may be converted to a compound of formula IIIa using the method depicted in Scheme 2.
  • reaction of a compound of formula IIa with a transition metal salt [M(L 1 L 2 )] n+ nA - provides a compound of formula IVa.
  • a compound of formula IIb provides the corresponding compound of formula IVb.
  • reaction of a compound of formula IIIb with a transition metal salt [M(L 1 L 2 )] n+ nA - provides a compound of formula Vb.
  • a compound of formula IIIa provides the corresponding compound of formula Va.
  • reaction of .a compound of formula XVI with a dichlorophosphine of formula VII, in a suitable solvent, in the presence of an alkyl magnesium chloride and hydrogen peroxide provides a phosphine oxide of formula XVII.
  • X O, S or NR 5 , PG 1 and PG 2 are suitable protecting groups such as methyl, benzyl, methoxymethyl etc.
  • Iodination of the phosphine oxide XVII, in a suitable solvent, in the presence of a suitable base provides the iodinated intermediate of formula XVIII. Deprotection of compound XVIII followed by cyclization, provides the corresponding cyclized intermediate of formula XIX.
  • Example 1 Preparation of tert -butyl(2,6-dimethoxyphenyl)(methyl)phosphine oxide (1).
  • dichloromethylphosphine (6.61 g, 57 mmol, 1.0 equiv.) in THF (50 mL) was added dropwise 1.0 M t BuMgCl (57 mL, 57 mmol, 1.0 equiv.) over 1 h while controlling the reaction temperature ⁇ -10°C.
  • the mixture was stirred at -10 to 0°C for 1 h and then warmed to 25°C over 1 h and stirred at 25°C for at least 1 h.
  • Example 2 Preparation of tert -butyl(2,6-dimethoxyphenyl)(iodomethyl)phosphine (2). To a solution of 1 (7.4 g, 28.9 mmol, 1 equiv.) and TMEDA (6.50 mL, 43 mmol, 1.5 equiv.) in THF (40 mL) at -78°C was added 2.5 M BuLi in hexanes (13.9 mL, 35 mmol, 1.2 equiv.) over 10 min. The resulting mixture was stirred at -78°C for 1 h.
  • Example 3 Preparation of racemic 3- tert -butyl-2,3-dihydrobenzo[d][1,3]oxaphosphol oxide -4-ol (3).
  • BBr 3 2,3-dihydrobenzo[d][1,3]oxaphosphol oxide -4-ol (3).
  • BBr 3 2,3-dihydrobenzo[d][1,3]oxaphosphol oxide -4-ol (3).
  • BBr 3 21.2 g, 64.8 mmol, 4 equiv.
  • Example 6 Preparation of (2 S ,2' S ,3 R ,3' R )-3,3'-di-tert-butyl-2,2',3,3'-tetrahydro-2,2'-bibenzo[ d ][1,3]oxaphosphole bisoxide ( 7a ).
  • 6a 155 mg, 0.737 mmol, 1 equiv
  • THF 4 mL
  • LDA 0.49 mL, 1.8 M in heptane/THF/chlorobenzene, 0.884 mmol, 1.2 equiv.
  • dichloromethane solution was washed with brine (10 mL), dried over sodium sulfate, concentrated, and purified by silica gel column chromatography (DCM:THF 3:1 1 to 2:1) to provide 7a (93 mg, 0.22 mmol, 60%) as white solid.
  • Example 7 Preparation of (2 S ,2' S ,3 S ,3' S )-3,3'-di-tert-butyl-2,2',3,3'-tetrahydro-2,2'-bibenzo[ d ][1,3]oxaphosphole bisoxide ( 8a ).
  • 8a To a solution of 7a (70 mg, 0.17 mmol, 1 equiv), triethylamine (169 mg, 1.7 mmol, 10 equiv) in toluene (10 mL) at 25°C was added trichlorosilane (114 mg, 0.84 mmol, 5 equiv). The mixture was heated to 80°C and stirred under nitrogen for 12 h.
  • Example 10 Preparation of ((2 S ,2' S ,3 R ,3' R )-3,3'-di- tert -butyl-4,4'-dimethoxy-2,2',3,3'-tetrahydro-2,2'-bibenzo[ d ][1,3]oxaphosphole bisoxide (7b).
  • 6b 150 mg, 0.624 mmol
  • THF 5 mL
  • LDA 0.416 mL, 0.749 mmol, 1.2 equiv
  • Example 11 (2 S ,2' S ,3 S ,3' S )-3,3'-di- tert -butyl-4,4'-dimethoxy-2,2',3,3'-tetrahydro-2,2'-bibenzo[ d ][1,3]oxaphosphole (8b).
  • 7b 100 mg, 0.209 mmol
  • triethylamine 422 mg, 4.18 mmol, 20 equiv
  • trichlorosilane (283 mg, 2.09 mmol, 10 equiv).
  • the mixture was heated to 80°C for 12 h, then cooled to 0°C and quenched with addition of degassed 30% NaOH solution (5 mL) over 5 min. The mixture was further stirred at 60°C for about 1 h until the two layers became clear.
  • the toluene layer was separated under N 2 and the aqueous layer was further extracted with toluene twice (5 mL X 2).
  • the combined toluene solution was dried over sodium sulfate, concentrated under N 2 , and purified by passing through a neutral alumina plug (eluent: hexanes/ether 5/1) to provide 8b (70 mg, 0.157 mmol, 75%) as a white solid.
  • Example 13 Preparation of ( R )-3-tert-butyl-4-phenyl-2,3-dihydrobenzo[d][1,3]oxaphosphole.
  • phenylboronic acid (1.02 g, 8.37 mmol, 1.5 equiv)
  • Pd 2 dba 3 153 mg, 0.17 mmol, 3 mol%)
  • PCy 3 (0.31 g, 1.12 mmol, 20 mol %)
  • potassium fluoride (1.30 g, 23.3 mmol, 4.0 equiv) was charged degassed dioxane (30 mL).
  • Example 14 Preparation of (2 S ,2' S ,3 R ,3' R )-3,3'-di- tert -butyl-4,4'-diphenyl-2,2',3,3'-tetrahydro-2,2'-bibenzo[ d ][1,3]oxaphosphole bisoxide (7c).
  • Compound 7c was prepared as a white solid (43%) under similar conditions to those described for compound 7b in Example 10 except that compound 6c was used instead of compound 6b.
  • Example 15 Preparation of (2 S ,2' S ,3 S ,3' S )-3,3'-di- tert -butyl-4,4'-diphenyl-2,2',3,3'-tetrahydro-2,2'-bibenzo[ d ][1,3]oxaphosphole ((2 S ,2' S ,3 S ,3' S )-Ph-BIBOP) ( 8c ).
  • Compound 8c was prepared as a white solid (84%) under similar conditions to those described for compound 8b in Example 11 except that compound 7c was used instead of compound 7b.
  • Example 16 Preparation of Rh[(2 S ,2' S ,3 S ,3' S )-Ph-BIBOP(nbd)]BF 4 ( 9c ).
  • Metal complex 9c was prepared as yellow-red solid (85%) under similar conditions to those described in Example 12 for compound 9b except that except that compound 8d was used instead of compound 8b:
  • Example 17 Preparation of ( R )-3-tert-butyl-4-methyl-2,3-dihydrobenzo[ d ][1,3]oxaphosphole (6d).
  • (R)-3 chiral triflate 0.5 g, 1.4 mmol
  • trimethylboroxine 0.21 g, 1.7 mmol, 1.2 equiv
  • Pd 2 dba 3 38 mg, 0.042 mmol, 3 mol%)
  • PCy 3 0.078 g, 0.28 mmol, 20 mol %)
  • potassium fluoride (0.33 g, 5.6 mmol, 4.0 equiv
  • Example 18 Preparation of (2 S ,2' S ,3 R ,3' R )-3,3'-di- tert -butyl-4,4'-dimethyl-2,2',3,3'-tetrahydro-2,2'-bibenzo[ d ][1,3]oxaphosphole bisoxide (7d).
  • Compound 7d was prepared as a white solid (74%) under similar conditions to those described for compound 7b in Example 10 except that compound 6d was used instead of compound 6b.
  • Example 19 Preparation of (2 S ,2' S ,3 S ,3' S )-3,3'-di- tert -butyl-4,4'-dimethyl-2,2',3,3'-tetrahydro-2,2'-bibenzo[ d ][1,3]oxaphosphole ((2 S ,2' S ,3 S ,3' S )-Me-BIBOP, 8d).
  • Compound 8d was prepared as a white solid (86%) under similar conditions to those described for compound 8b in Example 11 except that compound 7d was used instead of compound 7b.
  • Example 20 Preparation of Rh[(2 S ,2' S ,3 S ,3' S )-Me-BIBOP(nbd)]BF 4 (9d).
  • Metal complex 9d was prepared as a yellow-red solid (85%) under similar conditions to those described in Example 12 for compound 9b except that compound 8d was used instead of compound 8b.
  • Examples 21-23 describe the preparation of Rh[(2 S ,3 R )-3- tert -butyl-2-(di-tert-butylphosphino)-4-methoxy-2,3-dihydrobenzo[ d ][1,3]oxaphosphole (nbd)]BF 4 ( 10c ) as depicted below:
  • Example 21 Preparation of (2 S ,3 S )-3- tert -butyl-2-(di-tert-butylphosphino)-4-methoxy-2,3-dihydrobenzo[d][1,3]oxaphosphole bisoxide ( 10a ).
  • Example 22 Preparation of (2 S ,3 R )-3- tert -butyl-2-(di-tert-butylphosphino)-4-methoxy-2,3-dihydrobenzo[d][1,3]oxaphosphole ( 10b ).
  • 10a 0.12 g, 0.30 mmol
  • toluene 10 mL
  • triethylamine 0.61 g, 5.99 mmol, 20 equiv
  • trichlorosilane 0.41 g, 2.99 mmol
  • Example 23 Preparation of Rh[(2 S ,3 R )-3- tert -butyl-2-(di-tert-butylphosphino)-4-methoxy-2,3-dihydrobenzo[ d ][1,3]oxaphosphole (nbd)]BF 4 ( 10c ).
  • Rh(NBD) 2 BF 4 46 mg, 0.122 mmol
  • 10b 50 mg, 0.136 mmol, 1.1 equiv
  • the mixture was stirred at 25°C for 0.5 h, and then concentrated to about 1 mL.
  • Example 24 Preparation of (2 S ,3 S )-3- tert -butyl-2-(di-tert-butylphosphino)-2,3-dihydrobenzo[ d ][1,3]oxaphosphole bisoxide (11a).
  • Example 25 Preparation of (2 S ,3 R )-3-tert-butyl-2-(di-tert-butylphosphino)-2,3-dihydrobenzo[ d ][1,3]oxaphosphole (11b).
  • 11a (0.64 g, 1.73 mmol) in toluene (10 mL) at 25°C under nitrogen was added triethylamine (1.75 g, 17.3 mmol, 10 equiv) and trichlorosilane (1.40 g, 10.4 mmol, 6 equiv). The mixture was heated to 110°C for 3 d.
  • Example 26 Preparation of Rh[(2 S ,3 R )-3- tert -butyl-2-(di-tert-butylphosphino)-2,3-dihydrobenzo[d][1,3]oxaphosphole (nbd)]BF 4 (11c).
  • Rh(NBD) 2 BF 4 (0.27 g, 0.718 mmol) in THF (2 mL)
  • 11b 0.27 g, 0.798 mmol, 1.1 equiv
  • Example 27 Preparation of Rh[(2 R ,2' R ,3 R ,3' R )-BIBOP(nbd)]BF 4 .
  • Rh[(nbd)((2 R ,2' R ,3 R ,3' R )-BIBOP)]BF 4 (the H atoms are omitted) is shown in FIG. 1 .
  • Example 28 describes the use of the exemplary rhodium complex Rh[(nbd)((2 R ,2' R ,3 R ,3' R )-BIBOP)]BF 4 (from Example 27) for hydrogenation of ⁇ -arylenamides, ⁇ -dehydroamino acid derivatives, ⁇ -(acetylamino)acrylates, and dimethyl itaconate Entry Ar R ee [%] 1 Ph Me 99 2 p -MeO-Ph Me 99 3 p -Br-Ph Me 99 4 p -CF 3 -Ph Me >99 5 m -Me-Ph Me >99 6 3-thiophenyl Me >99 7 2-Naphthyl Me 98 8 p -Br-Ph CF 3 98 9 p -MeO-Ph t Bu 99 Entry Ar R R' ee [%] 1 Ph tBu Me 99 2 H Me Me >99 3 Ph Me Me 97 4 p -
  • Rh[(nbd)((2 R ,2' R ,3 R ,3' R )-BIBOP)]BF 4 is efficient for the enantioselective hydrogenation of ⁇ -arylenamides, ⁇ -dehydroamino acid derivatives, ⁇ -(acetylamino)acrylates, and dimethyl itaconate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Claims (15)

  1. Verbindung der Formel (Ia), (Ib) oder eine Mischung hiervon:
    Figure imgb0027
     worin:
    X O darstellt;
    R1 ist -(C1-C6)Alkyl, -CF3, -(C3-C10)Carbocyclyl, -(5- bis 11-gliedriges)Heterocarbocyclyl, -(C6-C10)Aryl, -(5 bis 11-gliedriges)Heteroaryl oder Ferrocenyl; wobei das -(C3-C10)Carbocyclyl, -(5- bis 11-gliedrige)Heterocarbocyclyl, -(C6-C10)Aryl, -(5 bis 11-gliedrige)Heteroaryl von R1 gegebenenfalls substituiert ist mit 1 bis 3 Substituenten, unabhängig ausgewählt aus -O(C1-C6)Alkyl, -(C1-C6)Alkyl und -CF3;
    R2 ist H, -O(C1-C6)Alkyl, -(C1-C6)Alkyl, -(C3-C10)Carbocyclyl, -(5- bis 11-gliedri-ges)Heterocarbocyclyl, -(C6-C10)Aryl, -(5 bis 11-gliedriges)Heteroaryl, -NR5R6 oder -SR5; wobei das -(C3-C10)Carbocyclyl, -(5- bis 11-gliedrige)Heterocarbocyclyl, -(C6-C10)Aryl und -(5 bis 11-gliedrige)Heteroaryl von R2 gegebenenfalls substituiert ist mit 1 bis 3 Substituenten, unabhängig ausgewählt aus -O(C1-C6)Alkyl, -(C1-C6)Alkyl und -CF3;
    R3 ist -PR7R8, -CH2PR7R8, -CH2OPR7R8 oder eine Gruppe der Formel (A) oder (B):
    Figure imgb0028
    worin X, R1 und R2 der Gruppe der Formel (A) oder (B) wie oben definiert sind, und wobei die Gruppe der Formel (A) sich nur an die Verbindung der Formel (Ia) bindet, und die Gruppe der Formel (B) sich nur an die Verbindung der Formel (Ib) bindet;
    R4 ist H, -(C1-C6)Alkyl, -(C3-C6)Cycloalkyl, -(3- bis 6-gliedriges)Heterocycloalkyl, Phenyl, (5- bis 6-gliedriges)Heteroaryl oder -SiR5 3; wobei das -(C1-C6)Alkyl von R4 gegebenenfalls substituiert ist mit 1 bis 3 Substituenten, unabhängig ausgewählt aus -O(C1-C6)Alkyl, -(C3-C6)Cycloalkyl, Phenyl und -(5- bis 6-gliedrigem)Heteroaryl; und wobei das -(C3-C6)Cycloalkyl, -(3- bis 6-gliedrige)Heterocycloalkyl, Phenyl und (5- bis 6-gliedrige)Heteroaryl von R4 gegebenenfalls substituiert ist mit 1 bis 3 Substituenten, unabhängig ausgewählt aus -O(C1-C6)Alkyl, -(C1-C6)Alkyl und -CF3;
    R5 und R6 sind jeweils unabhängig H, -(C1-C6)Alkyl, -CF3, -(C3-C10)Carbocyclyl, -(5- bis 11-gliedriges)Heterocarbocyclyl, -(C6-C10)Aryl oder -(5 bis 11-gliedriges)Heteroaryl; wobei jedes -(C1-C6)Alkyl, -CF3, -(C3-C10)Carbocyclyl, -(5- bis 11-gliedrige)Heterocarbocyclyl, -(C6-C10)Aryl und -(5 bis 11-gliedrige)Heteroaryl von R5 und R6 gegebenenfalls unabhängig substituiert ist mit 1 bis 3 Substituenten, unabhängig ausgewählt aus Halo, -O(C1-C6)Alkyl, -(C1-C6)Alkyl und -CF3; und
    R7 und R8 sind jeweils unabhängig -(C1-C6)Alkyl, -CF3, -(C3-C10)Carbocyclyl, -(5- bis 11-gliedriges)Heterocarbocyclyl, -(C6-C10)Aryl oder -(5 bis 11-gliedriges)Heteroaryl oder Ferrocenyl; wobei das -(C3-C10)Carbocyclyl, -(5- bis 11-gliedrige)Heterocarbocyclyl, -(C6-C10)Aryl oder -(5 bis 11-gliedrige)Heteroaryl von R7 und R8 jeweils gegebenenfalls unabhängig substituiert ist mit 1 bis 3 Substituenten, unabhängig ausgewählt aus -O(C1-C6)Alkyl, -(C1-C6)Alkyl und -CF3.
  2. Verbindung der Formel (Ia), (Ib) oder eine Mischung hiervon nach irgendeinem der vorhergehenden Ansprüche, wobei R1 -(C1-C6)Alkyl darstellt, ausgewählt aus -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -C(CH2CH3)3 oder -C(CH2CH3)(CH3)2.
  3. Verbindung der Formel (Ia), (Ib) oder eine Mischung hiervon nach irgendeinem der vorhergehenden Ansprüche, wobei R2 H, -CH3 oder -OCH3 darstellt.
  4. Verbindung der Formel (Ia), (Ib) oder eine Mischung hiervon nach irgendeinem der vorhergehenden Ansprüche, wobei R4 -H darstellt.
  5. Verbindung der Formel (Ia), (Ib) oder eine Mischung hiervon nach irgendeinem der vorhergehenden Ansprüche, wobei, R3 -PR7R8 darstellt oder eine Gruppe der Formel (A).
  6. Verbindung der Formel (Ia), (Ib) oder eine Mischung hiervon nach Anspruch 1, wobei R1 -C(CH3)3 darstellt; R2 ist -H, -CH3, -OCH3 oder Phenyl; und R3 ist -PR7R8.
  7. Verbindung der Formel (Ia), (Ib) oder eine Mischung hiervon nach Anspruch 1 oder 6, wobei R7 und R8 jeweils -C(CH3)3 darstellen und X O ist.
  8. Verbindung der Formel (Ia) nach irgendeinem der Ansprüche 1 bis 5, wobei R1 -C(CH3)3 darstellt; R2 ist -H, -CH3, -OCH3 oder Phenyl; und R3 ist eine Gruppe der Formel (A).
  9. Verbindung nach Anspruch 1 mit der Formel (IIa), (IIb) oder eine Mischung hiervon:
    Figure imgb0029
     worin
    R1 -CH(CH3)2, -C(CH3)3, -C(CH2CH3)(CH3)2, Cyclohexyl, 1-Adamantyl, Phenyl, ortho-Tolyl, 3,5-Xylyl, ortho-Anisyl oder Ferrocenyl darstellt; und
    R2 H, -OCH3, -CH3, -CF3, Phenyl oder -N(CH3)2 ist.
  10. Verbindung nach Anspruch 1 mit der Formel (IIIa), (IIIb) oder eine Mischung hiervon:
    Figure imgb0030
     worin
    R1 -CH(CH3)2, -C(CH3)3, -C(CH2CH3)(CH3)2, Cyclohexyl oder 1-Adamantyl darstellt;
    R2 ist H, -OCH3, -CH3, -CF3, Phenyl oder -N(CH3)2; und
    R7 und R8 sind jeweils -C(CH3)3.
  11. Verbindung nach Anspruch 1, ausgewählt aus:
    (2S,2'S,3S,3'S)-3,3'-Di-tert-butyl-2,2',3,3'-tetrahydro-2,2'-bibenzo[d][1,3]oxaphosphol,
    (2S,2'S,3S,3'S)-3,3'-Di-tert-butyl-4,4'-dimethoxy-2,2',3,3'-tetrahydro-2,2'-bibenzo[d][1,3]oxa-phosphol,
    (2S,2'S,3S,3'S)-3,3'-Di-tert-butyl-4,4'-diphenyl-2,2',3,3'-tetrahydro-2,2'-bibenzo[d][1,3]oxa-phosphol,
    (2S,2'S,3S,3'S)-3,3'-Di-tert-butyl-4,4'-dimethyl-2,2',3,3'-tetrahydro-2,2'-bibenzo[d][1,3]oxa-phosphol,
    (2S,3R)-3-tert-Butyl-2-(di-tert-butylphosphino-4-methoxy)-2,3-dihydrobenzo[d][1,3]oxaphosphol und
    (2S,3R)-3-tert-Butyl-2-(di-tert-butylphosphino)-2,3-dihydrobenzo[d][1,3]oxaphosphol.
  12. Metallkomplex der Formel (IVa), (IVb), (Va) oder (Vb):
    Figure imgb0031
    Figure imgb0032
     worin
    M ein Übergangsmetall darstellt, ausgewählt aus Co, Ni, Pd, Pt, Cu, Ag, Au, Ru, Fe, Rh und Ir;
    A- ist ein Gegenanion;
    n ist der Oxidationszustand des Übergangsmetalls M;
    L1 und L2 sind jeweils Olefine, oder L1 und L2 stellen zusammen ein Diolefin dar; und
    X, R1, R2, R7 und R8 sind wie in Anspruch 1 definiert.
  13. Metallkomplex nach Anspruch 12, wobei M Rh darstellt, A- ist BF4 - und n ist 1.
  14. Metallkomplex nach Anspruch 12, ausgewählt aus:
    Rh[(2S,2'S,3S,3'S)-3,3'-Di-tert-butyl-2,2',3,3'-tetrahydro-2,2'-bibenzo[d][1,3]oxaphosphol-(nbd)]BF4,
    Rh[(2S,2'S,3S,3'S)-3,3'-Di-tert-butyl-4,4'-dimethoxy-2,2',3,3'-tetrahydro-2,2'-bibenzo[d][1,3]-oxaphosphol(nbd)]BF4,
    Rh[(2S,2'S,3S,3'S)-3,3'-Di-tert-butyl-4,4'-diphenyl-2,2',3,3'-tetrahydro-2,2'-bibenzo[d][1,3]-oxaphosphol(nbd)]BF4,
    Rh[(2S,2'S,3S,3'S)-3,3'-Di-tert-butyl-4,4'-dimethyl-2,2',3,3'-tetrahydro-2,2'-bibenzo[d][1,3]-oxaphosphol(nbd)]BF4,
    Rh[(2S,3R)-3-tert-Butyl-2-(di-tert-butylphosphino)-4-methoxy-2,3-dihydrobenzo[d][1,3]oxa-phosphol(nbd)]BF4 und
    Rh[(2S,3R)-3-tert-Butyl-2-(di-tert-butylphosphino)-2,3-dihydrobenzo[d] [1,3]-oxaphosphol-(nbd)]BF4.
  15. Verfahren zur Durchführung einer asymmetrischen Hydrierung einer Verbindung mit einer Kohlenstoff-Kohlenstoff- oder Kohlenstoff-Heteroatom-Doppelbindung, wobei das Verfahren umfasst: Ermöglichen einer Umsetzung der Verbindung mit einer Kohlenstoff-Kohlenstoff- oder Kohlenstoff-Heteroatom-Doppelbindung mit Wasserstoff in Gegenwart einer katalytischen Menge des Metallkomplexes nach irgendeinem der Ansprüche 12 bis 14.
EP10774398.1A 2009-11-05 2010-11-01 Neue chirale phosphorliganden Not-in-force EP2496589B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25841709P 2009-11-05 2009-11-05
PCT/US2010/054912 WO2011056737A1 (en) 2009-11-05 2010-11-01 Novel chiral phosphorus ligands

Publications (2)

Publication Number Publication Date
EP2496589A1 EP2496589A1 (de) 2012-09-12
EP2496589B1 true EP2496589B1 (de) 2014-03-05

Family

ID=43587465

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10774398.1A Not-in-force EP2496589B1 (de) 2009-11-05 2010-11-01 Neue chirale phosphorliganden

Country Status (4)

Country Link
US (1) US8552212B2 (de)
EP (1) EP2496589B1 (de)
JP (1) JP5750449B2 (de)
WO (1) WO2011056737A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395081T3 (es) 2007-07-26 2013-02-08 Vitae Pharmaceuticals, Inc. Síntesis de inhibidores de la 11beta-hidroxiesteroide deshidrogenasa de tipo 1
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
US8440658B2 (en) 2007-12-11 2013-05-14 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
EP2252601B1 (de) 2008-01-24 2012-12-19 Vitae Pharmaceuticals, Inc. Cyclische carbazate und semicarbazide als inhibitoren von 11beta-hydroxysteroiddehydrogenase 1
WO2009102460A2 (en) 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5538365B2 (ja) 2008-05-01 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
ES2421537T3 (es) 2008-05-01 2013-09-03 Vitae Pharmaceuticals Inc Inhibidores cíclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
EP2323994A1 (de) 2008-07-25 2011-05-25 Boehringer Ingelheim International GmbH Synthese von inhibitoren von 11beta-hydroxysteroiddehydrogenase vom typ 1
JP5777030B2 (ja) 2008-07-25 2015-09-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
PL2324018T3 (pl) 2008-07-25 2014-02-28 Boehringer Ingelheim Int Cykliczne inhibitory dehydrogenazy 11 beta-hydroksysteroidowej typu 1
EP2393807B1 (de) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Zyklische 11beta-hydroxysteroid-dehydrogenase-1-hemmer
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
JP5656986B2 (ja) 2009-06-11 2015-01-21 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １，３−オキサジナン−２−オン構造に基づく１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
US8552212B2 (en) 2009-11-05 2013-10-08 Boehringer Ingelheim International Gmbh Chiral phosphorus ligands
EP2556077B1 (de) * 2010-04-05 2014-03-19 Boehringer Ingelheim International GmbH Monophosphorliganden und ihre verwendung bei kreuzkupplungsreaktionen
JP2013531636A (ja) 2010-05-26 2013-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−オキソ−１，２−ジヒドロピリジン−４−イルボロン酸誘導体
EP2582698B1 (de) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituierte 5-,6- und 7-gliedrige heterocyclen, medikamente mit derartigen verbindungen und ihre verwendung
JP5813106B2 (ja) 2010-06-25 2015-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
CA2813671A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
EP2920189B1 (de) 2012-11-15 2017-08-02 Boehringer Ingelheim International GmbH Verfahren zur herstellung neuartiger chiraler phosphorliganden
CN103087105B (zh) * 2013-01-18 2015-08-05 中国科学院上海有机化学研究所 手性膦配体以及包含该配体的金属催化剂和它们的应用
US9029540B2 (en) * 2013-07-01 2015-05-12 Boehringer Ingelheim International Gmbh Ruthenium catalysts and their use for asymmetric reduction of ketones
EP3019509B1 (de) * 2013-07-10 2019-09-11 Boehringer Ingelheim International GmbH Neuartige chirale stickstoff-phosphor-liganden und deren verwendung zur asymmetrischen hydrierung von alkenen
CN104558038B (zh) * 2013-10-23 2017-03-22 中国科学院上海有机化学研究所 一种取代的2，3‑二氢苯并[d][1，3]氧杂磷杂茂配体的制备方法
WO2015077286A1 (en) 2013-11-20 2015-05-28 Boehringer Ingelheim International Gmbh Hexahydroindenopyridine derivatives
CN104650145A (zh) * 2015-02-06 2015-05-27 中国科学院上海有机化学研究所 手性膦配体以及包含该配体的金属催化剂和它们的应用
CN105732249B (zh) * 2016-01-27 2019-03-15 中国科学院上海有机化学研究所 芳基醇类化合物及艾司西酞普兰合成方法
JP7069202B2 (ja) * 2016-12-06 2022-05-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規キラルジヒドロベンゾアザホスホール配位子及びその合成
JP2020500937A (ja) 2016-12-06 2020-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規キラルジヒドロベンゾオキサホスホール配位子及びその合成
CN107445999B (zh) * 2017-08-15 2020-11-13 中国科学院上海有机化学研究所 金属络合物、制备方法和应用及其中间体
CN107827929B (zh) * 2017-11-17 2020-03-10 中国科学院上海有机化学研究所 一种联芳基双膦配体、其制备方法及应用
CN109096338B (zh) * 2018-09-10 2020-05-12 中国科学院上海有机化学研究所 苯并氮杂磷杂茂膦氧配体及含其络合物、制备方法和应用
CN111018918B (zh) * 2018-10-10 2022-10-04 中国科学院上海有机化学研究所 一种金属配合物、中间体、其制备方法及应用
CN111848680B (zh) * 2019-04-30 2021-12-14 中国科学院上海有机化学研究所 双齿膦-膦氧配体及其中间体、制备方法和应用
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
CN111647020A (zh) * 2020-04-09 2020-09-11 宁波赜军医药科技有限公司 一种膦氧双齿配体的合成方法
CN113636950B (zh) 2020-05-11 2023-01-17 浙江医药股份有限公司新昌制药厂 一种手性4-芳基-β-氨基酸衍生物的制备方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681349A (en) 1970-03-05 1972-08-01 Morton Norwich Products Inc 1-(substituted benzyl) tetrahydro-2-(1h) pyrimidones
US5610294A (en) 1991-10-11 1997-03-11 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
US5521202A (en) 1993-04-07 1996-05-28 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivatives and pharmaceutical compositions containing the same
WO1996014297A1 (fr) 1994-11-04 1996-05-17 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de lactame
FR2729954B1 (fr) 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
US5776959A (en) 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
EP0928789B1 (de) 1996-07-31 2004-09-29 Nikken Chemicals Company, Limited 6-phenyltetrahydro-1,3-oxazin-2-on derivate und medizinische zusammensetzungen, die sie enthalten
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
JP2003507424A (ja) 1999-08-26 2003-02-25 ブリストル−マイヤーズ スクイブ カンパニー Ｎｐｙアンタゴニスト：スピロイソキノリノン誘導体
AU2097601A (en) 1999-12-17 2001-06-25 Schering Corporation Selective neurokinin antagonists
DE10034623A1 (de) 2000-07-17 2002-01-31 Bayer Ag Heterocyclisch substituierte Pyridine als Cytokin-Inhibitoren
US7169953B2 (en) 2001-11-09 2007-01-30 The Penn State Research Foundation P-chiral phospholanes and phosphocyclic compounds and their use in asymmetric catalytic reactions
WO2003057673A1 (en) 2001-12-28 2003-07-17 Bayer Pharmaceuticals Corporation 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
JP2006523710A (ja) 2003-04-16 2006-10-19 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４インヒビター
DE602005002253T2 (de) 2004-03-12 2008-05-29 Warner-Lambert Company Llc C1-symmetrische bisphosphinliganden und deren verwendung bei der asymmetrischen synthese von pregabalin
EP1747198B1 (de) 2004-05-07 2008-06-04 Janssen Pharmaceutica N.V. Adamantyl pyrrolidin-2-on-derivate als 11-beta hydroxysteroid dehydrogenas inhibitoren
WO2005116002A2 (en) 2004-05-24 2005-12-08 Amgen Inc. Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US20060009471A1 (en) 2004-06-24 2006-01-12 Wenqing Yao Amido compounds and their use as pharmaceuticals
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
EP1797054A2 (de) 2004-08-02 2007-06-20 OSI Pharmaceuticals, Inc. Arylaminosubstituierte pyrrolopyrimidine als multikinaseinhibierende verbindungen
ES2334246T3 (es) 2004-08-30 2010-03-08 Janssen Pharmaceutica Nv Derivados triciclos de adamantilamida como inhibidores de la 11-beta-hidroxiesteroide-deshidrogenasa.
UA87328C2 (en) 2004-08-30 2009-07-10 Янссен Фармацевтика Н.В. N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
JP5031568B2 (ja) 2004-09-10 2012-09-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドロゲン受容体モジュレーター（ｓａｒｍｓ）としての新規なイミダゾリジン−２−オン誘導体
WO2006040329A1 (en) 2004-10-12 2006-04-20 Novo Nordisk A/S 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds
US7713979B2 (en) 2004-10-29 2010-05-11 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
BRPI0607820A2 (pt) 2005-02-24 2010-03-23 Nihon Nohyaku Co Ltd derivado de haloalquilsulfonanilida ou um sal do mesmo, herbicida, e, mÉtodo para usar um herbicida
US20090264650A1 (en) 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
US8541592B2 (en) 2005-11-22 2013-09-24 Amgen Inc. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
EP1801098A1 (de) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylharnstoff Derivative als selektive 11B-HSD1 Inhibitoren
CA2635087A1 (en) 2005-12-30 2007-07-19 Merck & Co., Inc. Cholesteryl ester transfer protein inhibitors
US20070213311A1 (en) 2006-03-02 2007-09-13 Yun-Long Li Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
JP2007254409A (ja) 2006-03-24 2007-10-04 Taisho Pharmaceut Co Ltd イミダゾリジノン誘導体
WO2007124337A1 (en) 2006-04-21 2007-11-01 Eli Lilly And Company Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1
JP5161869B2 (ja) 2006-04-21 2013-03-13 イーライ リリー アンド カンパニー １１−β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤としての、シクロヘキシルピラゾール−ラクタム誘導体
AU2007240450B2 (en) 2006-04-21 2011-12-22 Eli Lilly And Company Cyclohexylimidazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PL2029529T3 (pl) 2006-04-24 2010-11-30 Lilly Co Eli PODSTAWIONE PIROLIDYNONY JAKO INHIBITORY DEHYDROGENAZY 11-ß-HYDROKSYSTEROIDOWEJ TYPU 1
PT2035379E (pt) 2006-04-25 2010-07-13 Lilly Co Eli Inibidores da 11-beta-hidroxiesterëide desidrogenase 1
US8927715B2 (en) 2006-08-25 2015-01-06 Vitae Pharmaceuticals, Inc. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
EP2104665A2 (de) 2006-10-19 2009-09-30 F. Hoffmann-Roche AG Imidazolon- und imidazolidinon-derivative als 11b-hsd1-inhibitoren gegen diabetes
TW200829171A (en) 2006-11-17 2008-07-16 Nihon Nohyaku Co Ltd Haloalkyl sulfonanilide derivatives or salts thereof, herbicide using it as effective constituent and use-method thereof
EP2125750B1 (de) 2007-02-26 2014-05-21 Vitae Pharmaceuticals, Inc. Zyklische harnstoff- und carbamat-hemmer aus 11-beta-hydroxysteroid-dehydrogenase 1
ES2395081T3 (es) 2007-07-26 2013-02-08 Vitae Pharmaceuticals, Inc. Síntesis de inhibidores de la 11beta-hidroxiesteroide deshidrogenasa de tipo 1
WO2009020140A1 (ja) 2007-08-06 2009-02-12 Dainippon Sumitomo Pharma Co., Ltd. アダマンチルウレア誘導体
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
US8859580B2 (en) 2007-11-16 2014-10-14 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
US8440658B2 (en) 2007-12-11 2013-05-14 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
EP2252601B1 (de) 2008-01-24 2012-12-19 Vitae Pharmaceuticals, Inc. Cyclische carbazate und semicarbazide als inhibitoren von 11beta-hydroxysteroiddehydrogenase 1
CA2714532A1 (en) 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
WO2009102460A2 (en) 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2265588B1 (de) 2008-02-27 2013-06-26 Vitae Pharmaceuticals, Inc. Inhibitoren von 11b-hydroxysteroiddehydrogenase von typ 1
CA2718264A1 (en) 2008-03-18 2009-09-24 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
TW200944526A (en) 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
JP5538365B2 (ja) 2008-05-01 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
ES2421537T3 (es) 2008-05-01 2013-09-03 Vitae Pharmaceuticals Inc Inhibidores cíclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
US8569292B2 (en) 2008-05-01 2013-10-29 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8242111B2 (en) 2008-05-01 2012-08-14 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
EP2323994A1 (de) 2008-07-25 2011-05-25 Boehringer Ingelheim International GmbH Synthese von inhibitoren von 11beta-hydroxysteroiddehydrogenase vom typ 1
JP5777030B2 (ja) 2008-07-25 2015-09-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
PL2324018T3 (pl) 2008-07-25 2014-02-28 Boehringer Ingelheim Int Cykliczne inhibitory dehydrogenazy 11 beta-hydroksysteroidowej typu 1
JP5589003B2 (ja) 2009-02-04 2014-09-10 ヴァイティー ファーマシューティカルズ，インコーポレイテッド 脂質障害のような代謝疾患の処置のために有用な［１，３］オキサジン−２−オンの誘導体
EP2393807B1 (de) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Zyklische 11beta-hydroxysteroid-dehydrogenase-1-hemmer
WO2010104830A1 (en) 2009-03-09 2010-09-16 Bristol-Myers Squibb Company Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
GEP20156309B (en) 2009-04-30 2015-07-10 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
JP5656986B2 (ja) 2009-06-11 2015-01-21 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １，３−オキサジナン−２−オン構造に基づく１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
EP2448928B1 (de) 2009-07-01 2014-08-13 Vitae Pharmaceuticals, Inc. CYCLISCHE 11ß-HYDROXYSTEROID-DEHYDROGENASE-1-HEMMER
US20110071115A1 (en) 2009-09-11 2011-03-24 Cylene Pharmaceuticals, Inc. Pharmaceutically useful heterocycle-substituted lactams
US8552212B2 (en) 2009-11-05 2013-10-08 Boehringer Ingelheim International Gmbh Chiral phosphorus ligands
EP2582698B1 (de) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituierte 5-,6- und 7-gliedrige heterocyclen, medikamente mit derartigen verbindungen und ihre verwendung
JP5813106B2 (ja) 2010-06-25 2015-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
CA2813671A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders

Also Published As

Publication number Publication date
US8552212B2 (en) 2013-10-08
WO2011056737A1 (en) 2011-05-12
JP2013510154A (ja) 2013-03-21
EP2496589A1 (de) 2012-09-12
US20120277455A1 (en) 2012-11-01
JP5750449B2 (ja) 2015-07-22

Similar Documents

Publication Publication Date Title
EP2496589B1 (de) Neue chirale phosphorliganden
EP3019509B1 (de) Neuartige chirale stickstoff-phosphor-liganden und deren verwendung zur asymmetrischen hydrierung von alkenen
JP4488739B2 (ja) Ｐ−キラルホスホランおよびホスホ環式化合物並びにその不斉触媒反応における使用
JP4167899B2 (ja) オルト置換キラルホスフィンおよびホスフィナイトならびに非対称触媒反応でのその使用
US6037500A (en) Asymmetric synthesis catalyzed by transition metal complexes with cyclic chiral phosphine ligands
KR100341258B1 (ko) 비대칭수소화촉매를위한신규비스포스핀
WO2005117907A2 (en) P-chiral phospholanes and phosphocyclic compounds and their use in asymmetric catalytic reactions
EP2556077B1 (de) Monophosphorliganden und ihre verwendung bei kreuzkupplungsreaktionen
US5274125A (en) Chirale phosphines
AU2011301115B2 (en) Biaryl diphosphine ligands, intermediates of the same and their use in asymmetric catalysis
US6573389B1 (en) Bidentate organophosphorous ligands and their use
US20050107608A1 (en) Ligands for use in catalytic processes
EP3551639B1 (de) Neuartige chirale dihydrobenzoazaphospholliganden und synthese davon
EP1595887A1 (de) Chirale C2-symmetrische Biphenyle, deren Herstellung sowie Metallkomplexe enthaltend diese Liganden und deren Verwendung als Katalysatoren in chirogenen Synthesen
US10544177B2 (en) Chiral dihydrobenzooxaphosphole ligands and synthesis thereof
JP4226847B2 (ja) ホスフィン−ホスホラン化合物と遷移金属とを含有する遷移金属錯体の存在下、α，β−不飽和アミド誘導体から光学活性アミド類を製造する方法。
US7465838B2 (en) Chiral diols, their manufacture and ligands and catalysts derived therefrom
CN111018918B (zh) 一种金属配合物、中间体、其制备方法及应用
CA2597883A1 (en) Catalyst for asymmetric synthesis, ligand for use therein, and process for producing optically active compound through asymmetric synthesis reaction using them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120605

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130426

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20130927

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 654817

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010014041

Country of ref document: DE

Effective date: 20140417

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 654817

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140305

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20140305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140605

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140705

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140605

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010014041

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140707

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

26N No opposition filed

Effective date: 20141208

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010014041

Country of ref document: DE

Effective date: 20141208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141101

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141130

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141101

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20101101

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20191121

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20191120

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20191120

Year of fee payment: 10

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602010014041

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20201101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210601

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201101